The FDA issued new guidance, titled “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Subgroups in Clinical Trials,” that calls for companies to submit a Race and Ethnicity Diversity Plan to include more underrepresented minority populations in the United States.

The U.S. Food and Drug Administration issued a new draft guidance to industry for developing plans to enroll more participants from underrepresented racial and ethnic populations in the U.S. into clinical trials –  expanding on the agency’s previous guidances for industry to improve clinical trial diversity.

On January 17, America is celebrating the legendary life of civil rights leader Dr. Martin Luther King Jr. In 2022, the holiday comes in the wake of two years of racial tensions and protests, and the racial inequities exposed by the COVID-19 pandemic. BioSpace is marking the occasion by sharing some of its recent coverage about what the life sciences industry is doing to even those scales.

The Covid-19 epidemic highlighted the disproportionate way the virus impacted minority communities across the U.S., increasing the calls for racial and ethnic diversity in clinical studies. While there has been a more significant push, a recent Pfizer clinical trials diversity report shows there is still a wide gap that needs to be bridged.

With global attention on gender and racial inequities this year, the Healthcare Businesswomen’s Association (HBA) is proud to recognize BD (Becton, Dickinson and Company) GSK, Surgical Care Affiliates and Walgreens Boots Alliance with 2020 ACE Awards for exemplary workplace initiatives that are working to close the gender and racial inequities in the healthcare and life sciences industry.

As the United States continues to grapple with race issues in the wake of the death of George Floyd, the leaders of Heartbeat issued their own call for more diversity and inclusion within the healthcare advertising industry, and within Heartbeat in particular.

A recent report in the New England Journal of Medicine reveals that the racial and ethnic minority groups most negatively impacted by Covid-19 are also the least represented in these clinical studies to develop vaccines and therapeutics aimed at the disease.

Numerous studies have found that in the U.S., minorities such as African Americans, Hispanics and Native Americans are often underrepresented in clinical trials. Regulatory agencies and various organizations are making an effort to address this issue.

Total U.S. coronavirus cases surpassed 2 million, according to a Reuters tally, as health officials urge anyone who took part in massive protests for racial justice to get tested.

In a first-of-its-kind effort, the Biotechnology Innovation Organization (BIO) conducted a survey that attempts to dive into diversity within the pharmaceutical and biotech industry.